Literature DB >> 23159547

Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF.

Robert J Mentz1, Adrian F Hernandez, Amanda Stebbins, Justin A Ezekowitz, G Michael Felker, Gretchen M Heizer, Dan Atar, John R Teerlink, Robert M Califf, Barry M Massie, Vic Hasselblad, Randall C Starling, Christopher M O'Connor, Piotr Ponikowski.   

Abstract

AIMS: To examine the characteristics associated with early dyspnoea relief during acute heart failure (HF) hospitalization, and its association with 30-day outcomes. METHODS AND
RESULTS: ASCEND-HF was a randomized trial of nesiritide vs. placebo in 7141 patients hospitalized with acute HF in which dyspnoea relief at 6 h was measured on a 7-point Likert scale. Patients were classified as having early dyspnoea relief if they experienced moderate or marked dyspnoea improvement at 6 h. We analysed the clinical characteristics, geographical variation, and outcomes (mortality, mortality/HF hospitalization, and mortality/hospitalization at 30 days) associated with early dyspnoea relief. Early dyspnoea relief occurred in 2984 patients (43%). In multivariable analyses, predictors of dyspnoea relief included older age and oedema on chest radiograph; higher systolic blood pressure, respiratory rate, and natriuretic peptide level; and lower serum blood urea nitrogen (BUN), sodium, and haemoglobin (model mean C index = 0.590). Dyspnoea relief varied markedly across countries, with patients enrolled from Central Europe having the lowest risk-adjusted likelihood of improvement. Early dyspnoea relief was associated with lower risk-adjusted 30-day mortality/HF hospitalization [hazard ratio (HR) 0.81; 95% confidence interval (CI) 0.68-0.96] and mortality/hospitalization (HR 0.85; 95% CI 0.74-0.99), but similar mortality.
CONCLUSION: Clinical characteristics such as respiratory rate, pulmonary oedema, renal function, and natriuretic peptide levels are associated with early dyspnoea relief, and moderate or marked improvement in dyspnoea was associated with a lower risk for 30-day outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23159547      PMCID: PMC3605752          DOI: 10.1093/eurjhf/hfs188

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  24 in total

1.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.

Authors: 
Journal:  JAMA       Date:  2002-03-27       Impact factor: 56.272

2.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).

Authors:  Kirkwood F Adams; Gregg C Fonarow; Charles L Emerman; Thierry H LeJemtel; Maria Rosa Costanzo; William T Abraham; Robert L Berkowitz; Marie Galvao; Darlene P Horton
Journal:  Am Heart J       Date:  2005-02       Impact factor: 4.749

3.  Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study.

Authors:  Marco Metra; John G Cleland; Beth Davison Weatherley; Howard C Dittrich; Michael M Givertz; Barry M Massie; Christopher M O'Connor; Piotr Ponikowski; John R Teerlink; Adriaan A Voors; Gad Cotter
Journal:  Eur J Heart Fail       Date:  2010-03-12       Impact factor: 15.534

Review 4.  Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE.

Authors:  John G F Cleland; Nick Freemantle; Alison P Coletta; Andrew L Clark
Journal:  Eur J Heart Fail       Date:  2006-01       Impact factor: 15.534

5.  The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study.

Authors:  Alexandre Mebazaa; Peter S Pang; Miguel Tavares; Sean P Collins; Alan B Storrow; Said Laribi; Stephanie Andre; Daniel Mark Courtney; Jennifer Hasa; Jindrich Spinar; Josep Masip; William Frank Peacock; Karen Sliwa; Etienne Gayat; Gerasimos Filippatos; John G F Cleland; Mihai Gheorghiade
Journal:  Eur Heart J       Date:  2009-11-11       Impact factor: 29.983

6.  Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).

Authors:  Adrian F Hernandez; Christopher M O'Connor; Randall C Starling; Craig J Reist; Paul W Armstrong; Kenneth Dickstein; Todd J Lorenz; W Brian Gibler; Vic Hasselblad; Michel Komajda; Barry Massie; John J V McMurray; Markku Nieminen; Jean L Rouleau; Karl Swedberg; Robert M Califf
Journal:  Am Heart J       Date:  2008-12-19       Impact factor: 4.749

7.  Low-dose nitroglycerin improves microcirculation in hospitalized patients with acute heart failure.

Authors:  Corstiaan A den Uil; Wim K Lagrand; Peter E Spronk; Martin van der Ent; Lucia S D Jewbali; Jasper J Brugts; Can Ince; Maarten L Simoons
Journal:  Eur J Heart Fail       Date:  2009-02-10       Impact factor: 15.534

Review 8.  Acute heart failure syndromes.

Authors:  Mihai Gheorghiade; Peter S Pang
Journal:  J Am Coll Cardiol       Date:  2009-02-17       Impact factor: 24.094

9.  Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.

Authors:  John R Teerlink; Marco Metra; G Michael Felker; Piotr Ponikowski; Adriaan A Voors; Beth Davison Weatherley; Alon Marmor; Amos Katz; Jacek Grzybowski; Elaine Unemori; Sam L Teichman; Gad Cotter
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

10.  Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group.

Authors:  Mihai Gheorghiade; Kirkwood F Adams; John G F Cleland; Gad Cotter; G Michael Felker; Gerasimos S Filippatos; Gregg C Fonarow; Barry H Greenberg; Adrian F Hernandez; Sadiya Khan; Michel Komajda; Marvin A Konstam; Peter P Liu; Aldo P Maggioni; Barry M Massie; John J McMurray; Mandeep Mehra; Marco Metra; John O'Connell; Christopher M O'Connor; Peter S Pang; Ileana L Piña; Hani N Sabbah; John R Teerlink; James E Udelson; Clyde W Yancy; Faiez Zannad; Norman Stockbridge
Journal:  Am Heart J       Date:  2009-06       Impact factor: 4.749

View more
  16 in total

1.  Treatment Approaches to Congestion Relief in Acute Decompensated HF: Insights After DOSE-AHF and CARRESS-HF.

Authors:  Simon F Shakar; JoAnn Lindenfeld
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-08

2.  The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF.

Authors:  Andrew P Ambrosy; Adrian F Hernandez; Paul W Armstrong; Javed Butler; Allison Dunning; Justin A Ezekowitz; G Michael Felker; Stephen J Greene; Padma Kaul; John J McMurray; Marco Metra; Christopher M O'Connor; Shelby D Reed; Phillip J Schulte; Randall C Starling; W H Wilson Tang; Adriaan A Voors; Robert J Mentz
Journal:  Eur J Heart Fail       Date:  2015-10-14       Impact factor: 15.534

3.  Relation of dyspnea severity on admission for acute heart failure with outcomes and costs.

Authors:  Robert J Mentz; Xiaojuan Mi; Puza P Sharma; Laura G Qualls; Adam D DeVore; Katherine Waltman Johnson; Gregg C Fonarow; Lesley H Curtis; Adrian F Hernandez
Journal:  Am J Cardiol       Date:  2014-10-15       Impact factor: 2.778

4.  Evaluation of a provocative dyspnea severity score in acute heart failure.

Authors:  Omar F AbouEzzeddine; Anuradha Lala; Prateeti P Khazanie; Ravi Shah; Jennifer E Ho; Horng H Chen; Peter S Pang; Steven E McNulty; Kevin J Anstrom; Adrian F Hernandez; Margaret M Redfield
Journal:  Am Heart J       Date:  2015-10-20       Impact factor: 4.749

5.  Mineralocorticoid Receptor Antagonism in Acute Heart Failure.

Authors:  Kemar Brown; Jennifer Chee; Stella Kyung; Bicky Vettichira; Lampros Papadimitriou; Javed Butler
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-09

Review 6.  Learning from recent trials and shaping the future of acute heart failure trials.

Authors:  Robert J Mentz; Gary Michael Felker; Tariq Ahmad; William Frank Peacock; Bertram Pitt; Mona Fiuzat; Aldo P Maggioni; Mihai Gheorghiade; Yuki Ando; Stuart J Pocock; Faiez Zannad; Christopher M O'Connor
Journal:  Am Heart J       Date:  2013-09-13       Impact factor: 4.749

7.  Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.

Authors:  Javed Butler; Adrian F Hernandez; Kevin J Anstrom; Andreas Kalogeropoulos; Margaret M Redfield; Marvin A Konstam; W H Wilson Tang; G Michael Felker; Monica R Shah; Eugene Braunwald
Journal:  JACC Heart Fail       Date:  2016-08-10       Impact factor: 12.035

8.  Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points.

Authors:  Stephen J Greene; Adrian F Hernandez; Jie-Lena Sun; Javed Butler; Paul W Armstrong; Justin A Ezekowitz; Faiez Zannad; João Pedro Ferreira; Adrian Coles; Marco Metra; Adriaan A Voors; Robert M Califf; Christopher M O'Connor; Robert J Mentz
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-10

9.  Assessment of dyspnea early in acute heart failure: patient characteristics and response differences between likert and visual analog scales.

Authors:  Peter S Pang; Sean P Collins; Kori Sauser; Adin-Cristian Andrei; Alan B Storrow; Judd E Hollander; Miguel Tavares; Jindrich Spinar; Cezar Macarie; Dimitar Raev; Richard Nowak; Mihai Gheorghiade; Alexandre Mebazaa
Journal:  Acad Emerg Med       Date:  2014-06       Impact factor: 3.451

Review 10.  Incorporating common biomarkers into the clinical management of heart failure.

Authors:  Meghana Halkar; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.